Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2).

Rosenberg JE, Hahn NM, Regan MM, Werner L, Alva A, George S, Picus J, Alter R, Balar A, Hoffman-Censits J, Grivas P, Lauer R, Guancial EA, Hoimes C, Sonpavde G, Albany C, Stein MN, Breen T, Jacobs C, Anderson K, Bellmunt J, Lalani AA, Pal S, Choueiri TK.

Br J Cancer. 2018 May 16. doi: 10.1038/s41416-018-0087-9. [Epub ahead of print]

PMID:
29765151
2.

The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.

McKay RR, Bossé D, Xie W, Wankowicz SAM, Flaifel A, Brandao R, Lalani AA, Martini DJ, Wei XX, Braun DA, Van Allen E, Castellano D, De Velasco G, Wells JC, Heng DY, Fay AP, Schutz FA, Hsu J, Pal SK, Lee JL, Hsieh JJ, Harshman LC, Signoretti S, Motzer RJ, Feldman D, Choueiri TK.

Cancer Immunol Res. 2018 Jul;6(7):758-765. doi: 10.1158/2326-6066.CIR-17-0475. Epub 2018 May 10.

PMID:
29748390
3.

Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma.

de Velasco G, Wankowicz SA, Madison R, Ali SM, Norton C, Duquette A, Ross JS, Bossé D, Lalani AA, Miller VA, Stephens PJ, Young L, Hakimi AA, Signoretti S, Pal SK, Choueiri TK.

Br J Cancer. 2018 May;118(9):1238-1242. doi: 10.1038/s41416-018-0064-3. Epub 2018 Apr 20.

PMID:
29674707
4.

Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events.

Martini DJ, Hamieh L, McKay RR, Harshman LC, Brandao R, Norton CK, Steinharter JA, Krajewski KM, Gao X, Schutz FA, McGregor B, Bossé D, Lalani AA, De Velasco G, Michaelson MD, McDermott DF, Choueiri TK.

Cancer Immunol Res. 2018 Apr;6(4):402-408. doi: 10.1158/2326-6066.CIR-17-0220. Epub 2018 Feb 1.

PMID:
29437040
5.

Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma.

Lalani AA, Xie W, Martini DJ, Steinharter JA, Norton CK, Krajewski KM, Duquette A, Bossé D, Bellmunt J, Van Allen EM, McGregor BA, Creighton CJ, Harshman LC, Choueiri TK.

J Immunother Cancer. 2018 Jan 22;6(1):5. doi: 10.1186/s40425-018-0315-0.

6.

Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression.

Lalani AA, Gray KP, Albiges L, Callea M, Pignon JC, Pal S, Gupta M, Bhatt RS, McDermott DF, Atkins MB, Woude GFV, Harshman LC, Choueiri TK, Signoretti S.

Oncotarget. 2017 Oct 23;8(61):103428-103436. doi: 10.18632/oncotarget.21952. eCollection 2017 Nov 28.

7.

JAVELIN: avelumab another spear to fight urothelial carcinoma.

Lalani AA, McGregor BA, Sonpavde GP, Choueiri TK.

Lancet Oncol. 2018 Jan;19(1):5-7. doi: 10.1016/S1470-2045(17)30901-4. Epub 2017 Dec 5. No abstract available.

PMID:
29217289
8.

Immunotherapy in the Elderly.

Lalani AA, Bossé D, McGregor BA, Choueiri TK.

Eur Urol Focus. 2017 Oct;3(4-5):403-412. doi: 10.1016/j.euf.2017.11.008. Epub 2017 Nov 26. Review.

PMID:
29183736
9.

Upper Tract Urothelial Carcinomas: Prognostic Factors and Outcomes in Patients With Non-Lymph Node Distant Metastasis.

Sevillano E, Werner L, Bossé D, Lalani AA, Wankowicz SAM, de Velasco G, Farina M, Lundgren K, Choueiri TK, González Del Alba A, Bellmunt J.

Clin Genitourin Cancer. 2017 Dec;15(6):e1089-e1094. doi: 10.1016/j.clgc.2017.07.012. Epub 2017 Aug 2.

PMID:
28864222
10.

Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series.

Martini DJ, Lalani AA, Bossé D, Steinharter JA, Harshman LC, Hodi FS, Ott PA, Choueiri TK.

J Immunother Cancer. 2017 Aug 15;5(1):66. doi: 10.1186/s40425-017-0273-y.

11.

Pan-urologic cancer genomic subtypes that transcend tissue of origin.

Chen F, Zhang Y, Bossé D, Lalani AA, Hakimi AA, Hsieh JJ, Choueiri TK, Gibbons DL, Ittmann M, Creighton CJ.

Nat Commun. 2017 Aug 4;8(1):199. doi: 10.1038/s41467-017-00289-x.

12.

Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma.

Lalani AA, McKay RR, Lin X, Simantov R, Kaymakcalan MD, Choueiri TK.

Clin Genitourin Cancer. 2017 Dec;15(6):724-732. doi: 10.1016/j.clgc.2017.05.019. Epub 2017 May 31.

PMID:
28645482
13.

First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience.

Lalani AA, Li H, Heng DYC, Wood L, Kalirai A, Bjarnason GA, Sim HW, Kollmannsberger CK, Kapoor A, Hotte SJ, Vanhuyse M, Czaykowski P, Reaume MN, Soulieres D, Venner P, North S, Basappa NS.

Can Urol Assoc J. 2017 Mar-Apr;11(3-4):112-117. doi: 10.5489/cuaj.4398.

Supplemental Content

Loading ...
Support Center